PepGen advances DM1 drug to highest dose after safety review

August 6, 2026 7:30 AM

PepGen Inc. (Nasdaq: PEPG) said an independent Data and Safety Monitoring Board (DSMB) has recommended advancing its Phase 2 FREEDOM2-DM1 ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found